Flavio G. Vincenti


Kidney and pancreas transplant specialist

Dr. Flavio Vincenti is a specialist in kidney and pancreas transplantation. He came to UCSF Medical Center in 1975 for a fellowship in transplant nephrology and was appointed a member of the kidney transplant team.

In 1978, Vincenti co-authored an article in the New England Journal of Medicine on the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and writer on the use of anti–interleukin 2 receptor monoclonal antibodies, used to reduce the chance of organ rejection. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Vincenti is a member of many professional organizations, including the Transplantation Society, American Society of Nephrology, American Society of Transplantation and International Society of Nephrology. He is a co-leader of the Immune Tolerance Network's kidney section. In addition, he is on the editorial boards of Graft and the American Journal of Kidney Diseases.

  • Education

    American University Medical Center of Beirut, 1971

  • Residencies

    American University Medical Center of Beirut, Internal Medicine

  • Fellowships

    Emory University Hospital, Nephrology, 1975

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Nephrology, American Board of Internal Medicine

  • Academic Title


  • Languages




Clinics I work with

Kidney Transplant Center

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

Pancreas Transplant Services

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

Selected research

Decorative Caduceus

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Definitions: Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection. Acute Antibody Mediated Rejection: Diffusely positive immun...


Decorative Caduceus

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

The safety of polyTregs will be described in comparison with CNI-based maintenance IS therapy.